To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
Not yet recruiting · NCT07364422 · Registry updated 2026-01-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-01-23 | NCT07364422 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Onconic Therapeutics Inc. | 9 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine | Seoul | South Korea | 2 |